AGY — Allergy Therapeutics Income Statement
0.000.00%
HealthcareSpeculativeSmall CapFalling Star
- £125.58m
- £94.12m
- £84.33m
- 59
- 31
- 22
- 27
Annual income statement for Allergy Therapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
2017 June 30th | 2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | |||||
Cost of Revenue | |||||
Gross Profit | |||||
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | |||||
Operating Profit | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | |||||
Provision for Income Taxes | |||||
Net Income After Taxes | |||||
Net Income Before Extraordinary Items | |||||
Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | |||||
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS |